One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial

Stefanie Schulz1*, MD; Adnan Kastrati1, MD; Miroslaw Ferenc2, MD; Steffen Massberg1, MD; Kathrin A. Birkmeier1, MD; Karl-Ludwig Laugwitz3, MD; Sebastian Kufner1, MD; Michael Gick2, MD; Michael Dommasch1, MD; Helmut Schühlen4, MD; Albert Schömig1,3, MD; Peter B. Berger5, MD; Julinda Mehilli1, MD; Franz-Josef Neumann2, MD; for the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 4 Trial Investigators

1. Deutsches Herzzentrum, Technische Universität, Munich, Germany; 2. Herz-Zentrum Bad Krozingen, Germany; 3. 1. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität, Munich, Germany; 4. Vivantes Auguste-Viktoria-Klin

Aims: Thirty-day results of the double-blind, randomised Intracoronary Stenting and Antithrombotic Regimen –Rapid Early Action for Coron

Sign in to read and download the full article

Login Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

abciximabbivalirudinclopidogrelheparinstent

Share on Facebook Share on Twitter Share on Linkedin

Read next article

Three-year outcome after percutaneous coronary intervention and coronary artery bypass grafting in patients with triple-vessel coronary artery disease: observations from the CREDO-Kyoto PCI/CABG registry cohort-2